The diabetes treatments Januvia and Byetta may double patients' risk of pancreatitis, a new study finds.
Sanofi is making a case for why its experimental diabetes drug Lyxumia stands out from existing GLP-1 therapies, as the French drug giant eyes the new med to build up its Lantus-led diabetes franchise amid relentless competition.
In one of the worst kept secrets in the industry, Sanofi has been in the scrum of potential buyers forming around Amylin in recent weeks.
After Amylin reportedly declined BMS' recent buyout offer, Bristol isn't giving up on its plans to gobble up the diabetes drugmaker, The Wall Street Journal reported.
Shares of Amylin Pharmaceuticals ($AMLN) rocketed up more than 40% this morning, fueled by a report that the Bydureon developer had turned down a $22 per share buyout offer from Bristol-Myers Squibb ($BMY).